Astera Labs Inc (ALAB) concluded trading on Wednesday at a closing price of $68.89, with 3.14 million shares of worth about $216.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 57.07% during that period and on Wednesday the price remained unchanged. Currently the company’s common shares owned by public are about 162.02M shares, out of which, 121.56M shares are available for trading.
Stock saw a price change of 0.10% in past 5 days and over the past one month there was a price change of -26.14%. Over the period of past 52 weeks, stock dropped to lowest price of $36.22 but also hit the highest price of $147.39 during that period. The average intraday trading volume for Astera Labs Inc shares is 5.33 million. The stock is currently trading -4.97% below its 20-day simple moving average (SMA20), while that difference is down -27.31% for SMA50 and it goes to -9.77% lower than SMA200.
Astera Labs Inc (NASDAQ: ALAB) currently have 162.02M outstanding shares and institutions hold larger chunk of about 58.30% of that.
The stock has a current market capitalization of $11.17B and its 3Y-monthly beta is at -0.15. It has posted earnings per share of -$0.54 in the same period. It has Quick Ratio of 11.21 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALAB, volatility over the week remained 5.97% while standing at 7.99% over the month.
Analysts are in expectations that Astera Labs Inc (ALAB) stock would likely to be making an EPS of 0.28 in the current quarter, while forecast for next quarter EPS is 0.3 and it is 1.72 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.28 which is 0.29 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.27 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 50.07% while it is estimated to increase by 36.22% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on March 14, 2025 offering an Outperform rating for the stock and assigned a target price of $82 to it. Coverage by Northland Capital stated Astera Labs Inc (ALAB) stock as an Outperform in their note to investors on January 28, 2025, suggesting a price target of $120 for the stock. On January 21, 2025, Morgan Stanley Downgrade their recommendations, while on January 02, 2025, Northland Capital Downgrade their ratings for the stock with a price target of $120. Stock get a Buy rating from Citigroup on November 18, 2024.
